Expertise in
8
conditions

Dr. Michael F. Guerrera

Pediatric Hematology Oncology
Children's Hospital
111 Michigan Ave Nw, 
Washington, DC 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
8
conditions
Children's Hospital
111 Michigan Ave Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Guerrera is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Guerrera is highly rated in 8 conditions, according to our data. His top areas of expertise are Hemophilia A, Blood Clots, Hemophilia B, and Hemophilic Arthropathy.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in VA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Innovation Health
  • HMO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 10 Less Insurance Carriers -

Locations

CHILDREN'S HOSPITAL
111 Michigan Ave Nw, Washington, DC 20010

Additional Areas of Focus

Dr. Guerrera has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease
A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease
Enrollment Status: Recruiting
Publish Date: April 30, 2025
Intervention Type: Biological
Study Drugs: Von Willebrand Factor, Factor VIII
Study Phase: Phase 3
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Genetic, Biological
Study Drug: AMT-061 Adeno-Associated Virus Padua Variant FIX Vaccine
Study Phase: Phase 3
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
Enrollment Status: Completed
Publish Date: February 12, 2025
US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia
US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia
Enrollment Status: Completed
Publish Date: February 01, 2023
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
Enrollment Status: Completed
Publish Date: December 09, 2021
Intervention Type: Biological
View 4 Less Clinical Trials

16 Total Publications

Invasive Intracranial Electroencephalography Monitoring in the Child with a Bleeding Disorder: Challenges and Considerations.
Invasive Intracranial Electroencephalography Monitoring in the Child with a Bleeding Disorder: Challenges and Considerations.
Journal: Pediatric neurosurgery
Published: April 18, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Sharon A. Savage
Pediatric Hematology Oncology
Expertise in
19
conditions
Dr. Sharon A. Savage
Pediatric Hematology Oncology
10 Center Drive, National Institutes Of Health Clinical Center, 
Bethesda, MD 
 (7.1 miles away)
240-276-7241
Languages Spoken:
English

Sharon Savage is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Savage is highly rated in 19 conditions, according to our data. Her top areas of expertise are Dyskeratosis Congenita, Aplastic Anemia, Aase Syndrome, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Expertise in
13
conditions
Dr. Blanche P. Alter
Pediatric Hematology Oncology
Expertise in
13
conditions
Dr. Blanche P. Alter
Pediatric Hematology Oncology
9609 Medical Center Dr, Room 6e452, 
Rockville, MD 
 (15.6 miles away)
240-276-7239
Languages Spoken:
English

Blanche Alter is a Pediatric Hematologist Oncology provider in Rockville, Maryland. Dr. Alter is highly rated in 13 conditions, according to our data. Her top areas of expertise are Aase Syndrome, Dyskeratosis Congenita, Aplastic Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Expertise in
6
conditions
Dr. Caterina P. Minniti
Pediatric Hematology Oncology
Expertise in
6
conditions
Dr. Caterina P. Minniti
Pediatric Hematology Oncology
111 Michigan Ave Nw, 
Washington, DC 
 (0.1 miles away)
202-884-2800
Languages Spoken:
English

Caterina Minniti is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Minniti is highly rated in 6 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Guerrera's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile